U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H19F3N2S.ClH
Molecular Weight 388.878
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIFLUPROMAZINE HYDROCHLORIDE

SMILES

Cl.CN(C)CCCN1C2=C(SC3=C1C=C(C=C3)C(F)(F)F)C=CC=C2

InChI

InChIKey=FTNWXGFYRHWUKG-UHFFFAOYSA-N
InChI=1S/C18H19F3N2S.ClH/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

HIDE SMILES / InChI

Description

Triflupromazine is antipsychotic and an antiemetic drug (sold under the brand names VESPRIN) which used to management of psychoses. However, this drug was discontinued. Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. Moreover, binds the muscarinic acetylcholine receptors (M1 and M2).

Approval Year

1957
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Muscarinic acetylcholine receptor M1
169
Target ID: P11229
Gene ID: 1128.0
Gene Symbol: CHRM1
Target Organism: Homo sapiens (Human)
Antagonist
2778
Muscarinic acetylcholine receptor M2
121
Target ID: P08172
Gene ID: 1129.0
Gene Symbol: CHRM2
Target Organism: Homo sapiens (Human)
Antagonist
2778
Antagonist
2778
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
VESPRIN

Approved Use

Used mainly in the management of psychoses. Also used to control nausea and vomiting

Launch Date

-3.87935994E11
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Overdose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
unhealthy
Health Status: unhealthy
Condition: Psychotic disorders
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
150 mg 1 times / day multiple, intramuscular
Recommended
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
unhealthy
Health Status: unhealthy
Condition: Psychotic disorders
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
3 mg 1 times / day multiple, intravenous
Recommended
Dose: 3 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / day
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
unhealthy
Health Status: unhealthy
Condition: Nausea
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
Sources:
http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9711
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9711
ZINC
ZINC000000538507
http://zinc15.docking.org/substances/ZINC000000538507
eMolecules
1989361
https://www.emolecules.com/cgi-bin/more?vid=1989361
PubMed

PubMed

TitleDatePubMed
Aluminum balance in intensive care patients.
2001 Apr
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
2001 Jul
Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents.
2002 Mar-Apr
Activation of Maxi Cl(-) channels by antiestrogens and phenothiazines in NIH3T3 fibroblasts.
2002 May
Triflupromazine: a microbicide non-antibiotic compound.
2004
Romifidine-ketamine anaesthesia in atropine and triflupromazine pre-medicated buffalo calves.
2004 Dec
Dissociation constants of phenothiazine drugs incorporated in phosphatidylcholine bilayer of small unilamellar vesicles as determined by carbon-13 nuclear magnetic resonance spectrometric titration.
2004 Feb 10
Effects of phosphatidylserine and phosphatidylethanolamine content on partitioning of triflupromazine and chlorpromazine between phosphatidylcholine-aminophospholipid bilayer vesicles and water studied by second-derivative spectrophotometry.
2005 Jan
Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials.
2005 Oct 17
Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods.
2006 Jul
Trypanosoma cruzi dihydrolipoamide dehydrogenase as target for phenothiazine cationic radicals. Effect of antioxidants.
2006 Sep
Modification of the thermal unfolding pathways of myoglobin upon drug interaction in different aqueous media.
2007 Dec 13
Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives.
2007 Mar 1
[Derivative spectrophotometric and NMR spectroscopic study in pharmaceutical science].
2007 Oct
Energetics of binding and protein unfolding upon amphiphilic drug complexation with a globular protein in different aqueous media.
2008 Jun 1
Monitoring the (photo)genotoxicity of photosensitizer drugs: direct quantitation of single-strand breaks in deoxyribonucleic acid using an oligonucleotide chip.
2008 Nov 1
Rapid method for the determination of tranquilizers and a beta-blocker in porcine and bovine kidney by liquid chromatography with tandem mass spectrometry.
2009 Apr 1
Inhibitors of clathrin-dependent endocytosis enhance TGFbeta signaling and responses.
2009 Jun 1
The effect of calmodulin antagonists on experimental scoliosis: a pinealectomized chicken model.
2009 Mar 15
Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation.
2009 Sep 15
Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine.
2010 Feb
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.
2010 Feb 23
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.
2010 Mar 3
Patents

Patents

20010006677
50
JP2002511777A
414

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Intramuscular
In Vitro Use Guide
Unknown
Name Type Language
TRIFLUPROMAZINE HYDROCHLORIDE
GREEN BOOK   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
TRIFLUPROMAZINE HCL
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [VANDF]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
NSC-14959
Code English
TRIFLUPROMAZINE HYDROCHLORIDE [MART.]
Common Name English
10-[3-(Dimethylamino)propyl]-2-(trifluoromethyl)phenothiazine monohydrochloride
Systematic Name English
TRIFLUPROMAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [JAN]
Common Name English
NSC-17473
Code English
TRIFLUPROMAZINE HYDROCHLORIDE [MI]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [USP-RS]
Common Name English
MC-4703
Code English
Triflupromazine hydrochloride [WHO-DD]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
10H-PHENOTHIAZINE-10-PROPANAMINE, N,N-DIMETHYL-2-(TRIFLUOROMETHYL)-, MONOHYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C740
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
CFR 21 CFR 522.2582
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
NCI_THESAURUS C29710
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C66636
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
NSC
14959
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
RS_ITEM_NUM
1686003
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
ChEMBL
CHEMBL570
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
FDA UNII
9E75N4A5HM
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
EVMPD
SUB04958MIG
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
RXCUI
91125
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
214-149-6
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
MERCK INDEX
m11123
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY Merck Index
NSC
17473
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
CAS
1098-60-8
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
EPA CompTox
DTXSID8045804
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
SMS_ID
100000084644
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
PUBCHEM
66069
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
DRUG BANK
DBSALT001039
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
CHEBI
9712
Created by admin on Sat Dec 16 05:13:19 UTC 2023 , Edited by admin on Sat Dec 16 05:13:19 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of TRIFLUPROMAZINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966